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Abstract
Introduction Thromboembolic complications are the most
frequent complications of endovascular treatment of ruptured
intracranial aneurysms. The optimal protocol to prevent
thromboembolic complications during coil embolization does
not yet exist. The aim of this study was to investigate the
effectiveness and safety of eptifibatide for the prevention of
thromboembolic complications during elective coil emboliza-
tion of ruptured cerebral aneurysms.
Methods A consecutive series of 100 patients (group 1) with
ruptured intracranial aneurysm were treated using
endovascular coil embolization. At the beginning of the pro-
cedure, all patients received an intra-arterial bolus (0.2 mg/kg)
of eptifibatide. The following data were collected: degree of
aneurysmal occlusion after treatment, thromboembolic and
hemorrhagic complications and other intraoperative adverse
events. The results were compared with those from a control
group (group 2) which were analyzed retrospectively. Group 2
consisted of 100 previous patients with ruptured aneurysm
managed with coil embolization who had received heparin
and/or aspirin at the beginning of the procedure.
Results (1) Patient populations in groups 1 and 2 were consid-
ered statistically comparable, except that group 1 (eptifibatide)
included more wide-necked aneurysms (p=0.011). (2) There
were less thromboembolic complications in group 1 (p=0.011):
seven intraoperative complications in group 1 versus 20 in
group 2. (3) Intraoperative hemorrhagic complications were
statistically comparable in both groups (p=1).
Conclusion Eptifibatide was effective in lowering the intra-
operative thromboembolic complication rate in ruptured an-
eurysms treated with coil embolization and did not increase
the hemorrhagic risk.
Keywords Aneurysm . Eptifibatide . Endovascular
procedure . Thromboembolic complication
Introduction
At present, there is no consensus on an optimal protocol to
prevent thromboembolic complications during coil emboliza-
tion of ruptured intracranial aneurysms. Despite IV adminis-
tration of heparin and/or aspirin intraoperatively, they still
remain the most frequent complications of coiling procedures.
Considering the increasing complexity of endovascular pro-
cedures, the increasing number of high-risk patients (i.e.,
elderly patients, large aneurysms, fusiform, or wide-necked
aneurysms) and the fact that these procedures sometimes
require the use of devices suspected of promoting thrombosis
(e.g., stents), it is high time that an effective and safe prophy-
lactic therapy protocol should be established.
According to the literature, the use of glycoprotein IIb/IIIa
inhibitors (GPIs) is a safe and effective rescue therapy [1, 2] for
thromboembolic complications occurring during endovascular
procedures. This is why we decided to use eptifibatide prophy-
lactically in patients treated for ruptured cerebral aneurysm
with endovascular coiling. A consecutive series of 100 patients
with ruptured intracranial aneurysm who had an emergency
endovascular treatment with intraoperative eptifibatide were
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included in a prospective study with the approval of the ethics
committee of the institution. All intraoperative and periopera-
tive bleeding and ischemic complications were recorded. The
results were compared with those achieved in a control group
consisting of 100 previous patients with ruptured aneurysm
who had endovascular treatment.
Patients and methods
Study design
The study compares two groups of consecutive patients with
ruptured aneurysms treated with coil embolization. One group
received an intra-arterial bolus (0.2 mg/kg) of eptifibatide at
the beginning of the procedure. The other group did not
receive eptifibatide but heparin and/or aspirin. This study
was designed, conducted, analyzed, and written independent-
ly of industry or any other financial support.
Group 1—population and procedures (Tables 1 and 2)
Between January 2012 and August 2013, 100 patients with
subarachnoid hemorrhage due to a ruptured aneurysm were
treated using coil embolization. These patients will be referred
to as group 1 later on in our study. All of them received an
intra-arterial bolus (0.2 mg/kg) of eptifibatide at the beginning
of the procedure.
Group 1 consisted of 39 male and 61 female patients.
Age ranged from 27 to 85 years (mean, 53 years; median,
55 years). Forty, out of these 100 patients, were smokers.
Associated comorbidities included chronic arterial hyperten-
sion (22), obesity, and overweight (9). At the time of the
hemorrhagic event, seven patients were on aspirin and two
on coumadin for atrial fibrillation. This had no impact on the
eptifibatide protocol.
Patients were classified according to the World Federation
of Neurosurgeons (WFNS) classification [3] and Fisher’s
classification (FC) [4] which uses computerized tomography
scans. Forty-four patients were WFNS 1, 25 WFNS 2, four
WFNS 3, 13 WFNS 4, and 14 WFNS 5. Five patients were
rated Fisher I, 26 Fisher II, 20 Fisher III, and 49 Fisher IV. In
27 patients (27 %), subarachnoid hemorrhage was associated
with a cerebral hematoma.
Ninety-six of the 100 emergency patients had one aneurysm,
and four had two aneurysms. Ninety-three aneurysms were
located in the anterior part of the circle of Willis and 11 in the
posterior circulation. The aneurysm size ranged from 1.5mm to
30 mm: maximal diameter was less than 10 mm in 79 aneu-
rysms and more than 10 mm in 25. Neck width ranged from
1.5 mm to 10 mm; 55 aneurysms had a broad neck (dome-to-
neck ratio <1.5 and/or neck ≥4 mm); and 49 a small neck.
Nineteen patients underwent simple endovascular coiling, 73 a
balloon remodeling procedure, and 12 endovascular coiling
using stent assistance. In the latter cases, 11 stents were required
in a broad neck and one as a rescue treatment.
In all patients, even those managed with simple coiling, a
remodeling balloon was routinely placed in the parent artery,
ready to be immediately inflated if aneurysm bleeding occurs.
Table 1 Population characteristics
Group 1
(eptifibatid)
Group 2 p value
Patients (n) 100 100
Aneurysms (n) 104 103
Sex (M/F) 38/62 36/64 0.77
Age Mean 55 53 0.308
Minimum 27 17
Maximum 85 79
Median 53 52
WFNS I 56 59 0.047
II 20 13 0.046
III 4 5 1
IV 9 14 1
V 11 9 0.375
Fisher I 5 3 0.72
II 26 32 0.531
III 20 16 0.581
IV 49 49 1
Angiographic vasospasm (n) 6 7 0.62
Cerebral hematoma (n) 27 19 0.239
Antiplatelet therapy
or anticoagulation
before intracranial
hemorrhage
Antiplatelet
therapy
(aspirin)
7 7 1
Coumadine 2 1
Ventriculostomy (n) 32 17 0.02
Table 2 Aneurysms and procedures
Group 1 (eptifibatid) Group 2 p value
Aneurysms (n) 104 103
Location ACI 24 30 0.345
Co Ant 41 48 0.327
MCA 23 16 0.286
ACA 5 3 0.721
Post Circ. 11 6 0.311
Size (>10 mm) 25 16 0.162
Neck (Large) 55 36 0.011
Procedures Coiling 19 27 0.184
Remodeling 73 71 0.885
Stenting 12 5 0.126
ACI internal carotid artery, Co Ant ant communicating artery, MCA
middle cerebral artery, ACA anterior cerebral artery, Post Circ., posterior
circulation
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All 100 patients were given the intra-arterial bolus of
eptifibatide after placement of the introducers. Three patients
who underwent a procedure longer than 5 h were given a
second bolus (0.2 mg/kg). The 12 patients in whom a stent
was used were loaded intraoperatively with 600 mg of
clopidogrel using a gastric tube, after the stent was deployed.
External ventricular drainage was used in 32 patients:
before coil embolization in 23 patients, within 4 h of
eptifibatide infusion in three, and during hospital stay in six.
After the procedure, the 12 stented patients were placed on
75 mg/day clopidogrel and 75 mg/day aspirin (started the next
day after the procedure). Among the other patients, 83 were
given 75 mg of aspirin once daily, three did not receive any
antiplatelet agent at all, and one was given heparin
intraoperatively.
All the patients had a CTscan of the head 24 h post-surgery.
Group 2—population and procedures (Tables 1 and 2)
Group 2 consisted of 100 consecutive patients with subarach-
noid hemorrhage due to a ruptured aneurysm who were treat-
ed using coil embolization before January 2012. In 98 pa-
tients, an IV bolus of heparin (5000 units) and aspirin
(260 mg) was given after placement of the introducers. Two
patients were given a bolus of heparin alone. As in group 1,
the five stented patients were loaded intraoperatively with
600 mg of plavix using a gastric tube, after the stent was
deployed.
Group 2 consisted of 36 male and 64 female patients with
age ranging from 17 to 79 years (mean, 53 years; median,
52 years). Forty-four, out of the 100 patients, were smokers.
The most commonly associated comorbidity was chronic
arterial hypertension (19). At the time of the hemorrhagic
event, seven patients were on aspirin and one on coumadin
for a history of pulmonary embolism.
Fifty-nine patients wereWFNS 1, 13WFNS 2, fiveWFNS
3, 14 WFNS 4, and nine WFNS 5. Three patients were rated
Fisher I, 32 Fisher II, 16 Fisher III, and 49 Fisher IV (19 of
whom had a cerebral hematoma).
In group 2, emergency procedures were performed in 103
aneurysms (three patients had two intracranial aneurysms that
were potentially responsible for the hemorrhagic event).
Ninety-seven aneurysms were located in the anterior part of
the circle of Willis and six in the posterior circulation. The
aneurysm size ranged from 1.5 mm to 45 mm: maximal
diameter was less than 10 mm in 87 and more than 10 mm
in 16. Neck width ranged from 1 mm to 8 mm; 36 aneurysms
had a broad neck (dome-to-neck ratio <1.5 and/or neck
≥4 mm), and 67 had a small neck.
Twenty-seven patients underwent simple endovascular
coiling, five endovascular coiling using stent assistance (two
stents were used as a rescue treatment), and 71 a balloon
remodeling procedure.
External ventricular drainage was used in 17 patients:
before coil embolization in 10 patients, immediately after the
procedure in two and during hospital stay in five.
After the procedure, eight patients were placed on a 75-mg/
day clopidogrel and 75-mg/day aspirin, 44 patients were given
75 mg of aspirin once daily, and 48 did not receive any
antiplatelet agent at all.
All patients had a CT scan of the head during their hospital
stay.
All patients in both groups were operated on by the same
two senior surgeons. Endovascular treatment in both groups
was performed within 48 h after diagnosis.
Analyzed parameters
The following parameters were analyzed in both groups:
– Intraoperative thromboembolic complications—these
complications were assessed using angiograms obtained
during the procedure or at the end of the procedure.
Angiographic findings were classified as follows: (1)
type I: partly occlusive thrombus at the coil-parent artery
junction or non-occlusive in-stent thrombus; (2) type II:
complete occlusion of a proximal arterial trunk (i.e. inter-
nal carotid artery (ICA), anterior communicating artery
(AComA), or middle cerebral artery (MCA)) or in-stent
thrombosis; and (3) type III: occlusion of distal arteries.
Thromboembolic complications were also categorized
into two groups: those requiring rescue therapy (mechan-
ical or chemical thrombectomy) and those which did not
require rescue therapy: small-size thrombus, non-
occlusive thrombus remaining stable over time, and/or
thrombus not involving an eloquent region of the brain.
– Cerebral and extracerebral hemorrhage after
endovascular treatment—intraoperative intracranial hem-
orrhage was evidenced either by contrast extravasation
on intraoperative angiography or by worsening of the
subarachnoid hemorrhage on the postoperative CT scan.
– Other intraoperative complications related to the proce-
dure or occurring during the procedure (e.g. coil
migration…).
– Rescue treatments for complications.
– Post-procedure aneurysm occlusion rate was assessed
using the modified Raymond classification [5].
CORELAB
Post-treatment CT scans were obtained for each patient and
compared by two vascular neurologists with the initial
preoperative scans. The aim was to evaluate the intracranial
bleeding status.
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Both the absence or occurrence of intraoperative thrombo-
embolic complications and the type of complications were
validated by a non-interventional neuroradiologist and a
neurovascular surgeon who reviewed and analyzed the angio-
grams obtained during the embolization procedure.
Statistics
The initial comparison of the two groups used univariate
analyses. The qualitative variables were compared using the
Pearson Chi-square test (or non-parametric Fisher’s exact
test), the quantitative variables were compared using Student’s
t test (or non-parametric Wilcoxon test).
Thromboembolic and hemorrhagic complication risk fac-
tors were assessed using univariate analyses.
All statistical analyses were performed by using the R3.0.2
software (Copyright (C) 2013. The R Foundation for Statisti-
cal Computing, Vienna, Austria).
Results
Initial comparability of groups 1 and 2 (Tables 1 and 2)
The vast majority of initial factors analyzed in the two groups
did not show any significant difference. Nevertheless, there
were more wide-necked aneurysms (p=0.011), and more pa-
tients requiring ventriculostomy (p=0.02) in group 1. There
were more WFNS 2 patients in group 1 (p=0.046) and more
WFNS 1 patients in group 2 (p=0.047).
Intraoperative thromboembolic complications were less
frequent in group 1 (p=0.011) (Table 3)
There were seven thromboembolic complications in group 1
(eptifibatide). Four of them were related to small-size thrombi
located distally in a non-eloquent region of the brain and did
not require rescue therapy. Three were related to non-
occlusive in-stent thrombi in two cases and to occlusion of a
middle cerebral artery trunk in one case. In all three cases, an
additional bolus of eptifibatide was given; in one of them, it
was associated with mechanical thrombectomy. It should be
pointed out that three of these seven complications occurred
during placement of a stent (altogether, 12 stents were used).
Twenty thromboembolic complications occurred in group
2: eight occlusions of a proximal trunk, eight distal occlusions,
and fur thrombi formed at the coil-parent artery junction. Two
complications occurred intraoperatively during placement of a
stent (two in five deployed stents).
In 19 out of the 20 complications, rescue treatments were
required consisting of in situ infusion of a bolus of eptifibatide
(0.2 mg/kg), plus mechanical thrombectomy in four patients.
Intra- and extracranial hemorrhagic complications were
comparable in both groups (p=1) (Table 3)
In group 1, four patients had intraoperative intracranial hem-
orrhage, which was evidenced by contrast extravasation on
intraoperative angiography. Bleeding was not spontaneous; it
occurred during coiling in three cases and resulted from me-
chanical perforation by themicrocatheter in one case. In all the
patients, inflation of the remodeling balloon and placement of
a coil stopped the hemorrhage. However, in one patient,
bleeding caused the development of a cerebral hematoma,
which led to patient’s death. In the other three patients, the
initial clinical condition remained unchanged.
In addition to these cerebral hemorrhagic complications,
three patients had groin hematoma with false arterial aneu-
rysm. No patient had retroperitoneal, gastrointestinal, or gen-
itourinary hemorrhage. The biological tests performed during
hospital stay did not reveal thrombocythemia.
In group 2, five patients had intraoperative bleeding. As in
group 1, rescue treatments consisted of inflation of the remod-
eling balloon and immediate coiling. One patient died from
intraoperative hemorrhage. In a further patient, the use of the
balloon allowed to stop bleeding but caused distal occlusion
of an artery. In the other three patients, intraoperative bleeding
was clinically inconsequential.
Two patients, in this group, had groin hematoma with
pseudoaneurysm of artery.
Table 3 Intraoperative complications
Overall thromboembolic
complications
Type Ia Type IIb Type IIIc Intraoperative intracranial
hemorrhage
Other
complications
Groin
Hematoma
Group 1 (eptifibatide) (100 patients) 7 2 1 4 4 7 3
Group 2 (100 patients) 20 4 8 8 5 6 2
p value 0.011 0.682 0.034 0.372 1 1 1
a Partly occlusive thrombus at the coil-parent artery junction or non-occlusive in-stent thrombus
b Complete occlusion of a proximal arterial trunk or in-stent thrombosis
c Occlusion of distal arteries
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Other intraoperative events were very similar in both groups
(p=1) (Table 3)
Intraoperative events in the eptifibatide group included severe
anaphylaxis reaction to anesthetic agents (1), acute neurogenic
pulmonary edema (1), mild dissection of the cervical carotid
artery (1), coil migration (1), coil fracture (1), coil herniation
(2, one of which resulted in a thromboembolic complication).
Intraoperative events in group 2 included acute neurogenic
pulmonary edema (1), coil herniation (3), and coil migration
(2). One of the three herniations and one of the two coil
migrations resulted in thromboembolic complications.
Aneurysmal occlusion
Aneurysmal occlusion rates were identical in both groups.
Overall, there were 26 Raymond grade 2 aneurysms and 77
Raymond grade 1. In group 1 which involved 104 aneurysms
(versus 103 in the control group), one patient was rated
Raymond grade 3 after treatment.
Discussion
Thromboembolic complications are the most frequent com-
plications of endovascular treatment of intracranial aneu-
rysms. [6–8]. The rate of thromboembolic events is heteroge-
neously reported in the series because of the different methods
of detection used: at clinical examination, at angiography, or at
diffusion-weighted MR imaging. The reported rate of throm-
boembolic complications usually ranges from 4.7 [8, 9] to
12.5 % [10]. Actually, if one considered the silent ischemic
injuries which would be detected postoperatively in more than
60 % of the patients on diffusion-weighted MR images, this
rate would likely be much higher [11, 12]. Intraoperative
thromboembolic complications may have extremely severe
clinical consequences. Recently, in a large series, they have
been found to be associated with 3.8 % permanent morbidity
andmortality [10]. According to Park et al. [13], in established
thromboembolic events, the mortality and permanent morbid-
ity rate could even exceed 20 and 40 %, respectively. Using a
large administrative database, Brinjiski et al. [1] have demon-
strated an intraoperative rescue therapy rate of approximately
7–8 % in endovascular coiling procedures.
The risk of intraoperative thromboembolic complications is
highly variable according to patients and aneurysms.
Smoking, diabetes [14, 15], age exceeding 65 years [16],
maximal aneurysm diameter >10 mm, broad-necked aneu-
rysm [10], and subarachnoid hemorrhage [17–19] (due to
activation of the coagulation system) are all risk factors.
It is also related to the technique used. In recent series [20],
remodeling balloons did not seem to be associated with an
increase in thromboembolic events. In contrast, emergency
stenting was associated with a higher risk of intraoperative
complications [21–23] including in-stent thrombosis, hemor-
rhagic complications which, according to Adamanta et al.,
would be attributable to the combined use of clopidogrel and
aspirin during the procedure [24].
Chalouhi [25] and Yi et al. [26] already used GPI prophy-
laxis (IIb/IIIa inhibitors) intraoperatively: Chalouhi when
coiling and stenting were associated in the same procedure,
and Yi et al. during endovascular coil embolization of rup-
tured and non-ruptured aneurysms. But the reported outcomes
are contradictory: Yi et al. [26] who gave a bolus of
eptifibatide to their patients stated that the use of IIb/IIIa
inhibitors was most hazardous, whereas Chalouhi et al. [25]
claimed that the use of tirofibran had not been associated with
morbidity or mortality.
Our study is the first prospective study about the effects of
GPI prophylaxis in endovascular treatment of ruptured aneu-
rysms. We had several good reasons to conduct this study:
– The absence of consensus on an optimal protocol to
prevent thromboembolic complications during coil em-
bolization of ruptured intracranial aneurysms
– Good results of the prophylactic use of antiplatelet agents
such as aspirin and clopidogrel in endovascular treatment
of non-ruptured aneurysms [27, 28]
– The major role played by platelet aggregation in the
development of thromboembolic complications and the
fact that GP IIb/IIIa are typically receptor antagonists [29,
30]
– Effectiveness of IIb/IIIa inhibitors in the treatment of
thromboembolic complications occurring during inter-
ventional neurovascular procedures [1], with complete
arterial recanalization in between 40 % [31] and 96 %
[32] of the patients
– Low hemorrhagic risk during infusion of IIb/IIIa inhibi-
tors in these rescue therapies [1, 2]
Eptifibatide is a selective and competitive GP IIb/IIIa re-
ceptor antagonist. Our deliberate choice of eptifibatide for our
study owes to its fast action following infusion. Eptifibatide
has a lower affinity for the GP IIb/IIIa receptor as compared to
abciximab. Furthermore, it shows rapid reversal of effects
(4 h) after infusion [33], which allows to perform more inva-
sive procedures (e.g. ventriculostomy) after endovascular
treatment.
In our study, eptifibatide significantly decreased the rate of
thromboembolic complications. And yet, there were more
wide-necked aneurysms in the eptifibatide group in which
the best results were achieved. Management of these compli-
cations was also very different in the two groups. In group 1,
only three out of seven thromboembolic events required res-
cue therapy and four events were considered potentially
Neuroradiology (2015) 57:197–203 201
inconsequential. In group 2, 19 out of 20 thromboembolic
events were judged severe enough to justify an attempt at
recanalization of the parent artery. This suggests that throm-
boembolic events were less severe in patients who received
eptifibatide, which is confirmed by the analysis of the types of
thromboembolic events: a smaller proportion of group 1 pa-
tients had complete occlusion of a proximal artery (Table 3;
p=0.034).
In our study, the prophylactic infusion of eptifibatide did
not increase the incidence or the severity of intraoperative
intracranial hemorrhage. None of the four aneurysmal perfo-
rations in group 1 occurred spontaneously after infusion of
eptifibatide. No bleeding complication was observed in group
1 after ventriculostomy, even for those for which external
ventricular drainage was performed within 4 h after injection
of eptifibatide (three patients). Despite these results, it makes
sense to preferentially perform ventriculostomy, prior to the
endovascular procedure, or more than 4 h after the eptifibatide
bolus. Similarly, extracerebral hemorrhagic complications
were not statistically more significant in the eptifibatide
group.
Obviously, there are several limitations to our study: study
population combines both retrospective and prospective data,
there are no short- and long-term clinical evaluations, analysis
of thromboembolic events is only based on intraoperative
angiography findings, and there is no postoperative MRI
evaluation. Additional studies are needed to confirm these
results to define what GPI to use and what is the best way to
administer it. Confirmation of our results would thus provide a
preventive treatment protocol that could be applied to
endovascular treatment of intracranial aneurysms ruptured,
and perhaps to the other brain endovascular procedures.
Conclusion
Prophylactic intraoperative use of eptifibatide in the
endovascular treatment of ruptured aneurysms allows to sig-
nificantly decrease the rate of thromboembolic complications
associated with this type of procedure and does not, in any
way, increases the rate of intraoperative hemorrhagic compli-
cations. Should further studies confirm these successful out-
comes, a standard treatment protocol could be developed and
guidelines could be established based on current practices.
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